Clinical Trials Browser

Phase 2 × Interventional × Multi-centric Castleman's Disease × Clear all

NCT05907759 2026-03-18

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Phase 2 Recruiting

LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT00092222 2026-03-11

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2 Active not recruiting

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Phase 2 Completed

8 enrolled 18 charts

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

NCT00132015 2012-03-15

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

Phase 2 Completed

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

Multi-centric Castleman's Disease, Angiolymphoid Hyperplasia with Eosinophilia, Burkitt Lymphoma, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Myeloproliferative Disorders, Polycythemia Vera, Precancerous Conditions, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma